Skip to content
Achieving equitable health outcomes begins in the lab, with equitable clinical trials, and we are now in a position to highlight and address inequity, […]
BIO’s Dr. McMurry-Heath on expanding the benefits of scientific progress Read More »
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the House of Representatives passed the Build
In Africa, cancer is 60% deadlier than malaria—and without action, the continent’s cancer burden is projected to get worse. “Should current trends continue, Africa’s
In Africa, cancer is deadlier than malaria – here’s what biotech’s doing about it Read More »
It’s the biggest vaccination campaign in American history—but not everyone’s on board. Phyllis Arthur, Biotechnology Innovation Organization (BIO) VP of Infectious Diseases and Emerging
I am BIO Podcast hears voices of vaccine hesitancy Read More »
As the world continues to deal with the impact of the COVID-19 pandemic, there remain many illnesses that require research and attention, including orphan
New hope for rare disease patients with founding of non-profit with for-profit model Read More »
To combat rising COVID-19 Delta cases nationwide, several states (and the federal government) are bringing back mask mandates and implementing vaccine mandates. Many other
States push anti-vax bills and executive orders Read More »
Nearly 400 leaders and funders of small biotechnology companies sent an open letter on September 8, 2021, to lawmakers explaining that drug price controls would
Small biotechs back alternatives to H.R. 3 Read More »
November is FOXG1 Awareness Month. We are amplifying some information from the FOXG1 Research Foundation about why this rare disease is prime for investment.
FOXG1 Awareness Month—and the need for investment in rare diseases like it Read More »
Greater transparency and competition are necessary, agreed Members of Congress and witnesses during a Republican-only forum on the Role of Pharmacy Benefit Managers in
PBMs must be included in drug pricing discussion Read More »
The development of vaccines targeting COVID-19 was remarkably swift, but it’s taking longer to respond to “the silent pandemic” of antimicrobial resistance. As World
The ‘silent pandemic’ of antimicrobial resistance Read More »
